Biohaven Pharmaceutical (NYSE:BHVN) insider Robert Berman sold 35,000 shares of the stock in a transaction dated Thursday, May 10th. The stock was sold at an average price of $26.82, for a total value of $938,700.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Robert Berman also recently made the following trade(s):

  • On Tuesday, April 10th, Robert Berman sold 35,000 shares of Biohaven Pharmaceutical stock. The stock was sold at an average price of $24.66, for a total value of $863,100.00.
  • On Monday, March 12th, Robert Berman sold 35,000 shares of Biohaven Pharmaceutical stock. The stock was sold at an average price of $30.11, for a total value of $1,053,850.00.

NYSE:BHVN opened at $28.68 on Tuesday. Biohaven Pharmaceutical has a 52 week low of $27.45 and a 52 week high of $28.52.

Biohaven Pharmaceutical (NYSE:BHVN) last posted its earnings results on Tuesday, March 6th. The company reported ($0.75) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.33) by $0.58. research analysts predict that Biohaven Pharmaceutical will post -4.34 earnings per share for the current year.

A number of hedge funds have recently bought and sold shares of BHVN. BlackRock Inc. boosted its holdings in Biohaven Pharmaceutical by 63.6% in the 1st quarter. BlackRock Inc. now owns 1,888,608 shares of the company’s stock worth $48,650,000 after buying an additional 734,401 shares during the last quarter. Alliancebernstein L.P. boosted its holdings in Biohaven Pharmaceutical by 84.9% in the 4th quarter. Alliancebernstein L.P. now owns 1,597,756 shares of the company’s stock worth $43,107,000 after buying an additional 733,526 shares during the last quarter. Carillon Tower Advisers Inc. acquired a new stake in Biohaven Pharmaceutical in the 4th quarter worth about $18,627,000. Millennium Management LLC acquired a new stake in Biohaven Pharmaceutical in the 4th quarter worth about $7,459,000. Finally, Eagle Asset Management Inc. boosted its holdings in Biohaven Pharmaceutical by 20.4% in the 4th quarter. Eagle Asset Management Inc. now owns 1,104,999 shares of the company’s stock worth $30,207,000 after buying an additional 187,243 shares during the last quarter. Institutional investors own 63.34% of the company’s stock.

A number of research firms have recently commented on BHVN. Zacks Investment Research upgraded Biohaven Pharmaceutical from a “hold” rating to a “buy” rating and set a $33.00 target price on the stock in a research report on Friday, March 9th. Barclays cut Biohaven Pharmaceutical from an “overweight” rating to an “equal weight” rating and dropped their target price for the company from $30.00 to $25.00 in a research report on Thursday, April 5th. Canaccord Genuity restated a “buy” rating and set a $39.00 target price (up from $30.00) on shares of Biohaven Pharmaceutical in a research report on Thursday, February 22nd. ValuEngine upgraded Biohaven Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. Finally, Needham & Company LLC restated a “buy” rating on shares of Biohaven Pharmaceutical in a research report on Thursday, February 22nd. One research analyst has rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $37.14.

Biohaven Pharmaceutical Company Profile

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops product candidates to treat neurological diseases, including rare disorders. Its lead product candidate is rimegepant, which is in Phase III clinical trials for the acute treatment of migraine. The company also develops trigriluzole, which is in a Phase II/III clinical trial used for the treatment of ataxias with an initial focus on spinocerebellar ataxia; and Phase II/III clinical trial for the treatment of obsessive compulsive disorders, as well as for the treatment of Alzheimer's diseases.

Insider Buying and Selling by Quarter for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.